Lung-Targeting Peptide Modified AAV Vectors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current viral vectors lack sufficient specificity for targeting lung tissue, leading to inadequate transduction and severe immune reactions during systemic administration for pulmonary hypertension treatment.
Innovation Solution
Development of recombinant viral vectors with a novel lung-specific peptide sequence, such as ESGHGYF, that binds specifically to lung endothelial cells, allowing for targeted gene delivery and reduced immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional viral vectors are used for systemic administration, then gene delivery can be achieved, but tissue specificity is insufficient leading to inadequate transduction of lung tissue
Solution Approach 1:
The patent applies local quality by modifying the viral capsid with a lung-specific peptide sequence (ESGHGYF) that confers selective binding capability to lung endothelial cells. This localized functional modification enables the vector to distinguish and preferentially transduce lung tissue while maintaining its overall structure and gene delivery mechanism.
2Reliability
If conventional viral vectors are used for systemic administration, then gene delivery can be achieved, but severe immune reactions occur
Solution Approach 1:
The lung-specific peptide sequence acts as an intermediary that mediates selective interaction between the viral vector and lung endothelial cells. This intermediary component enables targeted delivery while reducing non-specific immune recognition and systemic immune reactions, as the vector is directed to its intended target rather than distributing throughout the body.
3Reliability
If lung-specific peptide sequence is incorporated into viral capsid, then tissue specificity is improved, but vector complexity increases
Solution Approach 1:
The patent applies segmentation by separating the viral vector into distinct functional modules: the conventional viral capsid structure that provides gene delivery capability, and the added lung-specific peptide sequence that provides targeting functionality. This modular approach allows the peptide to be independently optimized and exchanged without redesigning the entire vector system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vectors achieve strong and persistent transgene expression in lung tissue with minimal immune response, enabling effective gene therapy for pulmonary disorders.
Implementation Method 1
a peptide, polypeptide, or protein that binds specifically to cells of the lung endothelium
Data Source
AI summary
The invention relates to a peptide, polypeptide, or protein that binds specifically to cells of the lung endothelium. The peptide, polypeptide, or protein can be a component of a viral capsid and can be used to lead a recombinant viral vector selectively to the lung endothelial tissue after systemic administration to a subject and to ensure tissue-specific expression of one or more transgenes there. The invention thus further relates to a recombinant viral vector, preferably an AAV vector, which comprises a capsid comprising the peptide, polypeptide, or protein according to the invention and which comprises at least one transgene packaged in the capsid. The viral vector is suitable in particular for the therapeutic treatment of a lung disorder or a lung disease. The invention further relates to cells and pharmaceutical compositions which comprise the viral vector according to the invention.